Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 12 · below the Ichimoku cloud · RSI 37 · MACD below its signal
None of the 29 investors followed here reported a position in 1167.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 1167.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for 1167.HK.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.4 | 4.7 | 11.8 | 1.3 | -30.0 | -2.4 | -2.3 | 34.9 | -3.8 | -15.5 | −19.6% | ||
| 2025 | 11.8 | 69.0 | 60.4 | 0.0 | 50.6 | -25.2 | 93.8 | -3.6 | 22.1 | -25.5 | 8.0 | -20.1 | +401.6% |
| 2024 | -30.1 | -6.7 | -31.4 | 4.3 | -7.7 | 0.0 | 8.3 | -1.2 | 13.8 | -3.2 | -19.0 | -14.8 | −64.9% |
| 2023 | 22.4 | 37.0 | -17.2 | -5.2 | -14.5 | 0.0 | -21.4 | -17.5 | -16.0 | 19.4 | -0.5 | -4.7 | −30.8% |
| 2022 | -35.4 | -9.4 | -6.4 | 1.4 | -13.0 | -12.9 | -29.2 | 25.7 | -22.5 | -17.8 | 31.5 | 14.9 | −63.9% |
| 2021 | 42.0 | -0.2 | -20.1 | 18.9 | 17.6 | -2.7 | -14.6 | -0.5 | 1.5 | -5.7 | -9.5 | -9.5 | +2.7% |
| 2020 | — |
Buy / hold / sell counts
Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatment of patients with locally advanced or metastatic solid tumors. It is also developing IND-enabling candidates, including JAB-BX467, JAB-BX600, and JAB-BX700 for solid tumor indications. The company has a collaboration agreement with AstraZeneca AB to develop and commercialize JAB-23E73. Jacobio Pharmaceuticals Group Co., Ltd. was founded in 2015 and is headquartered in Beijing, China.
No recent headlines.